PA83-FhCMB
/ iBio
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 15, 2022
Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against Bacillus anthracis: A Phase 1 dose-escalation study in healthy adults.
(PubMed, Vaccine)
- P1 | "This is the first study demonstrating a plant-derived subunit anthrax vaccine's safety and immunogenicity in healthy adults. The results support further clinical investigation of the PA83-FhCMB vaccine. ClinicalTrials.gov identifier. NCT02239172."
Journal • P1 data
February 17, 2019
Transient expression of an anthrax decoy protein in Nicotiana benthamiana: The impacts of N-glycosylation on protein expression, stability and function
(ACS-Sp 2019)
- "The toxin neutralization potency of CMG2-Fc variants was tested in a cell-based assay, where the EC50 values for APO and Agly variants were lower than for the ER-retained variant. The possible causes of EC50 differences were investigated through molecular simulation and protein thermostability studies."
February 17, 2019
Transient expression of an anthrax decoy protein in Nicotiana benthamiana: The impacts of N-glycosylation on protein expression, stability and function
(ACS-Sp 2019)
- "The toxin neutralization potency of CMG2-Fc variants was tested in a cell-based assay, where the EC50 values for APO and Agly variants were lower than for the ER-retained variant. The possible causes of EC50 differences were investigated through molecular simulation and protein thermostability studies."
1 to 3
Of
3
Go to page
1